TACSTD2 and neoplasm: Trophoblast cell surface antigen 2 (Trop-2), an epithelial antigen overexpressed in about 57% of endometrioid endometrial cancer, is associated with poor prognosis and higher tumor grades [55], representing a potential treatment target.